Evidence map›Paper›PMID 32033116›Full record

ArticleInternational journal of molecular sciences2020

Antioxidant Role of PRGF on RPE Cells after Blue Light Insult as a Therapy for Neurodegenerative Diseases.

Carlota Suárez-Barrio, Susana Del Olmo-Aguado, Eva García-Pérez, María de la Fuente, Francisco Muruzabal, Eduardo Anitua, Begoña Baamonde-Arbaiza, Luis Fernández-Vega-Cueto, Luis Fernández-Vega, Jesús Merayo-Lloves

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Carlota Suárez-BarrioInstituto Universitario Fernández-Vega. Fundación de Investigación Oftalmológica & Universidad de Oviedo, 33012 Oviedo, Spain.
Susana Del Olmo-AguadoInstituto Universitario Fernández-Vega. Fundación de Investigación Oftalmológica & Universidad de Oviedo, 33012 Oviedo, Spain.
Eva García-PérezInstituto Universitario Fernández-Vega. Fundación de Investigación Oftalmológica & Universidad de Oviedo, 33012 Oviedo, Spain.
María de la FuenteBTI Biotechnology Institute, 01007 Vitoria, Spain.
Francisco MuruzabalBTI Biotechnology Institute, 01007 Vitoria, Spain.
Eduardo AnituaBTI Biotechnology Institute, 01007 Vitoria, Spain.
Begoña Baamonde-ArbaizaInstituto Universitario Fernández-Vega. Fundación de Investigación Oftalmológica & Universidad de Oviedo, 33012 Oviedo, Spain.
Luis Fernández-Vega-CuetoInstituto Universitario Fernández-Vega. Fundación de Investigación Oftalmológica & Universidad de Oviedo, 33012 Oviedo, Spain.
Luis Fernández-VegaInstituto Universitario Fernández-Vega. Fundación de Investigación Oftalmológica & Universidad de Oviedo, 33012 Oviedo, Spain.
Jesús Merayo-LlovesInstituto Universitario Fernández-Vega. Fundación de Investigación Oftalmológica & Universidad de Oviedo, 33012 Oviedo, Spain.

Funding

Instituto de Salud Carlos III- of the Spanish Ministry of Economy and Competitiveness, and the European Union through the "Fondo Europeo de Desarrollo Regional (FEDER)". PI17/01549
6 · The paper itself

Abstract

Oxidative stress has a strong impact on the development of retinal diseases such as age-related macular degeneration (AMD). Plasma rich in growth factors (PRGF) is a novel therapeutic approach in ophthalmological pathologies. The aim of this study was to analyze the antioxidant effect of PRGF in retinal epithelial cells (EPR) in in vitro and ex vivo retinal phototoxicity models. In vitro analyses were performed on ARPE19 human cell line. Viability and mitochondrial status were assessed in order to test the primary effects of PRGF. GSH level, and protein and gene expression of the main antioxidant pathway (Keap1, Nrf2, GCL, HO-1, and NQO1) were also studied. Ex vivo analyses were performed on rat RPE, and HO-1 and Nrf2 gene and protein expression were evaluated. The results show that PRGF reduces light insult by stimulating the cell response against oxidative damage and modulates the antioxidant pathway. We conclude that PRGF's protective effect could prove useful as a new therapy for treating neurodegenerative disorders such as AMD.

Indexed as

AdultAnimalsAntioxidantsCell LineCell SurvivalEpithelial CellsFemaleHumansIntercellular Signaling Peptides and ProteinsLightMitochondriaNeurodegenerative DiseasesOxidation-ReductionOxidative StressPlasmaRatsAntioxidantsIntercellular Signaling Peptides and ProteinsReactive Oxygen SpeciesAge-related macular degeneration (AMD)antioxidantARPE19blue lightneurodegenerative diseaseplasma rich in growth factors (PRGF)reactive oxygen species (ROS)retinal pigment epithelium (RPE)

Identifiers

PMID32033116
PMCPMC7037919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.